Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter ...

Ethereum co-founder Vitalik Buterin laid out a quantum resistance roadmap targeting four key vulnerabilities in the network’s cryptography.

Titled “The 2028 Global Intelligence Crisis,” the viral essay by Citrini Research and Alap Shah paints a catastrophic picture ...

AI-enhanced optical spectroscopy revolutionizes food quality monitoring with rapid, non-destructive analysis, ensuring safety and reducing waste in production.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Those that solve artificially simplified problems where quantum advantage is meaningless. Those that provide no genuine quantum advantage when all costs are properly accounted for. This critique is ...

DeepSeek compares China and US AI lab conditions; standardized schooling vs interest-driven training shapes early talent development.

Former NYDIG and Two Sigma executives are building Five Bells Settlement to tackle counterparty risk in digital assets settlement using Bitcoin-native technology.

Oracle-based quantum algorithms cannot use deep loops because quantum states exist only as mathematical amplitudes in Hilbert space with no physical substrate. Criticall ...

AI startup Anthropic's claim of automating COBOL modernization sent IBM's stock plummeting, wiping billions off its market value. The decades-old language, still powering critical systems, faces a ...

The new version of the container and VM manager extends GPU support for AMD hardware and introduces cluster recovery ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...